- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 02.09. | 20/20 Biolabs, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 19.08. | 20/20 BioLabs Cancer-Test Revenue Jumps 47% As Firefighter Screening Programs Expand | 1 | pulse2.com | ||
| 17.08. | 20/20 Biolabs, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 17.08. | 20/20 Biolabs Q2 GAAP EPS of -$0.26, revenue of $0.73M | 1 | Seeking Alpha | ||
| 20/20 BIOLABS Aktie jetzt für 0€ handeln | |||||
| 17.08. | 20/20 Biolabs Inc.: 20/20 BioLabs Reports Second Quarter 2026 Financial Results and Recent Operational Progress, as Cancer Test Revenue Reaches Record Quarterly Level | 210 | GlobeNewswire (Europe) | Best Quarter of Flagship Multi-Cancer Early Detection Testing; OneTest Revenue Increased 47% Year-Over-Year to $0.7 Million; Gross Profit Increased 87% to $0.3 Million, with Gross Margin Expanding... ► Artikel lesen | |
| 05.08. | 20/20 Biolabs, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 27.07. | 20/20 BioLabs meets potential partners in East Asia | 1 | Investing.com | ||
| 27.07. | 20/20 Biolabs Inc.: 20/20 BioLabs Participates in BIO Asia-Taiwan and Meets with Strategic Counterparties in Taipei, Tokyo, and Seoul to Advance East Asia Roll-Up Strategy | 1 | GlobeNewswire (USA) | ||
| 23.07. | 20/20 Biolabs Inc.: 20/20 BioLabs Announces Standstill Agreement with Streeterville Capital Regarding Series E Convertible Preferred Stock | 179 | GlobeNewswire (Europe) | Agreement Temporarily Restricts Preferred-to-Common Stock Conversions Below a Defined Price Threshold, Mitigating Potential Near-Term Dilution GAITHERSBURG, Md., July 23, 2026 (GLOBE NEWSWIRE) --... ► Artikel lesen | |
| 22.07. | 20/20 Biolabs, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 09.07. | 20/20 BioLabs reports Q2 MCED revenue to be highest to date | 1 | Investing.com | ||
| 01.07. | 20/20 Biolabs, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 27.05. | 20/20 Biolabs Inc.: 20/20 Biolabs' Multi-Cancer Early Detection Blood Test Selected by State of Vermont to Screen up to 4,500 Firefighters | 3 | GlobeNewswire (USA) | ||
| 22.05. | 20/20 Biolabs: Pläne für Ebola-Tests treiben Aktie an | 1 | Investing.com Deutsch | ||
| 22.05. | 20/20 Biolabs Inc.: 20/20 Biolabs Commences Emergency Planning for Ebola & Hantavirus Lab Testing if Outbreak Creates Overflow Demand | 2 | GlobeNewswire (USA) | ||
| 20.05. | 20/20 Biolabs, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 20.05. | 20/20 Biolabs, Inc. GAAP EPS of -$0.28 misses by $0.18, revenue of $0.35M misses by $0.43M | 1 | Seeking Alpha | ||
| 20.05. | 20/20 Biolabs, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 12.05. | 20/20 Biolabs Inc.: 20/20 BioLabs Exclusively Licenses PSA Velocity Algorithm from the University of South Carolina | 1 | GlobeNewswire (USA) | ||
| 28.04. | 20/20 Biolabs, Inc. - 8-K, Current Report | - | SEC Filings |
1 2 Weiter >>
32 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| TENON MEDICAL | 5,850 | -1,35 % | Tenon Medical Announces Warrant Inducement for Aggregate Gross Proceeds of Approximately $2,872,338 | LOS GATOS, CA / ACCESS Newswire / September 11, 2026 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a medical device company dedicated to transforming care for patients with certain... ► Artikel lesen | |
| FRESENIUS | 45,040 | +0,75 % | EQS-DD: Fresenius SE & Co. KGaA: Michael Sen, Kauf | Meldung und öffentliche Bekanntgabe der Geschäfte von Personen, die Führungsaufgaben wahrnehmen, sowie in enger Beziehung zu ihnen stehenden Personen
08.09.2026 / 11:02... ► Artikel lesen | |
| SIEMENS HEALTHINEERS | 38,230 | -0,49 % | EQS-CMS: Siemens Healthineers AG: Veröffentlichung einer Kapitalmarktinformation | EQS Zulassungsfolgepflichtmitteilung: Siemens Healthineers AG
/ Bekanntmachung nach Art. 5 Abs. 1 lit. b), Abs. 3 der Verordnung (EU) Nr. 596/2014, zuletzt geändert durch die Verordnung... ► Artikel lesen | |
| FRESENIUS MEDICAL CARE | 38,440 | -0,13 % | EQS-CMS: Fresenius Medical Care AG: Veröffentlichung einer Kapitalmarktinformation | EQS Zulassungsfolgepflichtmitteilung: Fresenius Medical Care AG
/ Bekanntmachung nach Art. 5 Abs. 1 lit. b) der Verordnung (EU) Nr. 596/2014
Fresenius Medical Care AG: Veröffentlichung... ► Artikel lesen | |
| PROGYNY | 27,350 | 0,00 % | Progyny auf Gesundheitskonferenz von Wells Fargo: Wachstumsperspektiven bleiben intakt | ||
| BRIGHTSPRING HEALTH SERVICES | 58,73 | 0,00 % | BTSG Gains More Than 54% YTD: Should You Buy, Hold or Sell? | ||
| LIFESTANCE HEALTH GROUP | 12,975 | +0,04 % | LifeStance Health Group, Inc. - 8-K, Current Report | ||
| HEARTFLOW | 49,850 | -0,06 % | Heartflow, Inc.: Late Breaking Data from Independent Government-Funded Trial at ESC Shows Heartflow FFRCT Analysis Reduces Unnecessary Invasive Heart Procedures by Nearly Half | FUSION trial presented at ESC and published in Journal of the American College of Cardiology demonstrates adding non-invasive lesion-specific physiology resolves critical diagnostic uncertainty, supporting... ► Artikel lesen | |
| ALIGNMENT HEALTHCARE | 12,610 | 0,00 % | Alignment Healthcare USA, LLC: Alignment Health's Fifth Annual Survey Finds Seniors Falling Further Behind: Aging in Place Challenges Continue to Rise as Support Gaps Widen | ||
| CARL ZEISS MEDITEC | 30,300 | -2,38 % | 411 Milliarden US-Dollar Schaden pro Jahr: Warum Augengesundheit für Carl Zeiss Meditec, Alcon & Co. zum Technologiemarkt wird - und wo Rise Nano Optics ins Spiel kommt | ||
| AVEANNA HEALTHCARE | 14,060 | -0,14 % | Biotech Stocks At 52-Week Highs - Park Dental Partners +10%, Aveanna Healthcare +24%, Candel Therapeutics +10% on Q2 Reports, Labcorp Holdings, Hemab Therapeutics | LONDON (dpa-AFX) - The following biotech stocks reached 52-week highs on August 13, 2026, driven by key catalysts such as positive quarterly reports and the issuance of increased guidance figures.Park... ► Artikel lesen | |
| PROCEPT BIOROBOTICS | 20,370 | -0,15 % | Oppenheimer reiterates Procept BioRobotics stock rating | ||
| GERRESHEIMER | 28,220 | -2,62 % | EQS-DD: Gerresheimer AG: Active Ownership Opportunities SCS, Kauf | Meldung und öffentliche Bekanntgabe der Geschäfte von Personen, die Führungsaufgaben wahrnehmen, sowie in enger Beziehung zu ihnen stehenden Personen
07.09.2026 / 15:24... ► Artikel lesen | |
| GENEDX | 85,16 | -0,12 % | GeneDx: Starkes Wachstum trifft auf schwachen Forderungseinzug | ||
| PRIVIA HEALTH GROUP | 20,420 | 0,00 % | Privia Health Group, Inc.: Privia Health Announces Appointment of Opella Ernest, M.D. to its Board of Directors | ARLINGTON, Va., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (Nasdaq: PRVA) announced the appointment of Opella Ernest, M.D. to its Board of Directors, effective September 1, 2026.... ► Artikel lesen |
Das Unternehmen 20/20 BIOLABS INC kann der Branche Gesundheitswesen zugeordnet werden. Die relative Kursveränderung beträgt aktuell -1,57 % bei einem Aktienkurs von 0,551 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu 20/20 BIOLABS INC finden Sie auf Wallstreet Online.